Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Authors:
Open Access
- 1 December 2014
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 14 (6) , 405-412
Abstract
No abstract availableKeywords
Funding Information
- Eisai Inc
This publication has 36 references indexed in Scilit:
- Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancerJournal of Cancer Research and Clinical Oncology, 2013
- Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group TrialClinical Breast Cancer, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancerAnnals of Oncology, 2011
- Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparisonBMC Cancer, 2010
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialBreast Cancer Research and Treatment, 2009
- Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial GroupBreast Cancer Research and Treatment, 2009
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnnals of Oncology, 2007